BET inhibitors are small molecules designed to block the interaction between BET proteins and acetylated histones. By preventing this interaction, BET inhibitors can disrupt the expression of oncogenes and other cancer-related genes, leading to reduced tumor growth and potentially inducing cancer cell death. Several BET inhibitors, such as JQ1, OTX015, and CPI-0610, are currently being tested in clinical trials for their efficacy against different types of cancer.
